search icon
alec-img

Alector Inc, Common Stock

ALEC

NSQ

$1.42

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$130.99M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
638.17K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.76
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.87 L
$6.78 H
$1.42

About Alector Inc, Common Stock

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALECSectorS&P500
1-Week Return8.4%0.71%0.79%
1-Month Return25.66%-5.6%6.04%
3-Month Return-13.41%-11.72%-1.11%
6-Month Return-45.17%-10.81%-2.39%
1-Year Return-71.6%-7.12%11.69%
3-Year Return-83.97%-0.57%42.29%
5-Year Return-95.66%27.64%93.12%
10-Year Return-92.15%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue21.10M207.09M133.62M97.06M100.56M[{"date":"2020-12-31","value":10.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":64.52,"profit":true},{"date":"2023-12-31","value":46.87,"profit":true},{"date":"2024-12-31","value":48.56,"profit":true}]
Cost of Revenue156.87M189.41M8.47M192.12M8.84M[{"date":"2020-12-31","value":81.65,"profit":true},{"date":"2021-12-31","value":98.59,"profit":true},{"date":"2022-12-31","value":4.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":4.6,"profit":true}]
Gross Profit21.10M207.09M133.62M(95.05M)91.72M[{"date":"2020-12-31","value":10.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":64.52,"profit":true},{"date":"2023-12-31","value":-45.9,"profit":false},{"date":"2024-12-31","value":44.29,"profit":true}]
Gross Margin100.00%100.00%100.00%(97.93%)91.21%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-97.93,"profit":false},{"date":"2024-12-31","value":91.21,"profit":true}]
Operating Expenses216.27M244.44M271.45M248.80M245.56M[{"date":"2020-12-31","value":79.67,"profit":true},{"date":"2021-12-31","value":90.05,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.66,"profit":true},{"date":"2024-12-31","value":90.46,"profit":true}]
Operating Income(195.17M)(37.36M)(137.83M)(151.74M)(145.00M)[{"date":"2020-12-31","value":-19517400000,"profit":false},{"date":"2021-12-31","value":-3736000000,"profit":false},{"date":"2022-12-31","value":-13783400000,"profit":false},{"date":"2023-12-31","value":-15174000000,"profit":false},{"date":"2024-12-31","value":-14499700000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(190.23M)(36.33M)(130.06M)(125.18M)(118.92M)[{"date":"2020-12-31","value":-19022800000,"profit":false},{"date":"2021-12-31","value":-3632900000,"profit":false},{"date":"2022-12-31","value":-13005600000,"profit":false},{"date":"2023-12-31","value":-12517900000,"profit":false},{"date":"2024-12-31","value":-11892100000,"profit":false}]
Income Taxes(7.26M)(8.31M)3.25M5.21M128.00K[{"date":"2020-12-31","value":-139.39,"profit":false},{"date":"2021-12-31","value":-159.54,"profit":false},{"date":"2022-12-31","value":62.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":2.46,"profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(190.23M)(36.33M)(133.31M)(141.38M)(119.05M)[{"date":"2020-12-31","value":-19022800000,"profit":false},{"date":"2021-12-31","value":-3632900000,"profit":false},{"date":"2022-12-31","value":-13331000000,"profit":false},{"date":"2023-12-31","value":-14138500000,"profit":false},{"date":"2024-12-31","value":-11904900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(182.96M)(28.01M)(133.31M)(130.39M)(119.05M)[{"date":"2020-12-31","value":-18296300000,"profit":false},{"date":"2021-12-31","value":-2801400000,"profit":false},{"date":"2022-12-31","value":-13331000000,"profit":false},{"date":"2023-12-31","value":-13039100000,"profit":false},{"date":"2024-12-31","value":-11904900000,"profit":false}]
EPS (Diluted)(2.44)(0.54)(1.61)(1.55)(1.23)[{"date":"2020-12-31","value":-244,"profit":false},{"date":"2021-12-31","value":-54,"profit":false},{"date":"2022-12-31","value":-161,"profit":false},{"date":"2023-12-31","value":-155,"profit":false},{"date":"2024-12-31","value":-123,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALEC
Cash Ratio 3.23
Current Ratio 3.34

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALEC
ROA (LTM) -17.22%
ROE (LTM) -90.26%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALEC
Debt Ratio Lower is generally better. Negative is bad. 0.77
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.23

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALEC
Trailing PE NM
Forward PE 526.32
P/S (TTM) 1.61
P/B 1.50
Price/FCF NM
EV/R 2.38
EV/Ebitda NM

FAQs

What is Alector Inc share price today?

Alector Inc (ALEC) share price today is $1.42

Can Indians buy Alector Inc shares?

Yes, Indians can buy shares of Alector Inc (ALEC) on Vested. To buy Alector Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALEC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alector Inc be purchased?

Yes, you can purchase fractional shares of Alector Inc (ALEC) via the Vested app. You can start investing in Alector Inc (ALEC) with a minimum investment of $1.

How to invest in Alector Inc shares from India?

You can invest in shares of Alector Inc (ALEC) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALEC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alector Inc shares
What is Alector Inc 52-week high and low stock price?

The 52-week high price of Alector Inc (ALEC) is $6.78. The 52-week low price of Alector Inc (ALEC) is $0.87.

What is Alector Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alector Inc (ALEC) is 1.50

What is the Market Cap of Alector Inc?

The market capitalization of Alector Inc (ALEC) is $130.99M

What is Alector Inc’s stock symbol?

The stock symbol (or ticker) of Alector Inc is ALEC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top